Gonadotrophin-releasing Hormone Therapy in Hypogonadal Males with Hypothalamic or Pituitary Dysfunction

127Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Subcutaneous self-administration of synthetic gonadotrophin-releasing hormone 500 [µg eight-hourly for up to one year by 12 male patients (five prepubertal) with clinical hypogonadism due to hypothalamic or pituitary disease resulted in the synthesis and continued release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). There was a rise in circulating androgen levels in all patients. Improvements in pubertal ratings were seen in some prepubertal patients. Potency returned in the adults and spermatogenesis was induced and maintained in the four patients who had received treatment for more than four months, total counts reaching between 7.8 and 432 x 10 spermatozoa. A fall in the FSH response to the releasing hormone occurred during spermatogenesis though LH was little affected. During the initial weeks of therapy FSH secretion usually occurred before that of LH though LH secretion was greater as treatment continued. FSH secretion also persisted for longer when treatment was stopped. © 1974, British Medical Journal Publishing Group. All rights reserved.

Cite

CITATION STYLE

APA

Murray, M. A. F., McNeilly, A. S., Fisher, R. A., & Besser, G. M. (1974). Gonadotrophin-releasing Hormone Therapy in Hypogonadal Males with Hypothalamic or Pituitary Dysfunction. British Medical Journal, 4(5945), 617–621. https://doi.org/10.1136/bmj.4.5945.617

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free